anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A device, system, and method determines when to select limited echocardiography exams. The method is performed at a workflow server. The method includes receiving an image order for a patient, the image order including information indicative of a reason to perform an image acquisition procedure. The method includes determining whether the patient has had a prior image acquisition procedure performed within a time threshold relative to the image order. The method includes when the prior image acquisition procedure had been performed within the time threshold, determining whether the reason requires a number of views within a view threshold. The method includes when the number of views is within the view threshold, generating an indication that the image acquisition procedure is to be performed with a limited capacity.
Narcotics and/or anaesthetics for injection into mammals contain a sufficient amt of (a) a steroid of the pregnane gps which displays anaesthetic and/or narcotic effect when injected intravenously (e.g. 3alpha-hydroxy-5beta-pregnant-20-one) (which compounds are potent and rapid acting, and cause little or no irritation of vascular tissue when injected) together with (b) a potentiator such as a 1, 4-benzodiazepine paraldehyde, chloral hydrate or a glycerol phenyl ether of formula (I): (where R1 and R2 are lower alkyl, m and n are 0 or positive integers the sum of which is not >5, and R3 is H or amino), together with (c) an injectable aqs. org. solvent in an amt which is sufficient for an injection prepn. The potentcy of the narcotic/anaesthetic steroid is greatly increased by the potentiator. The pref. potentiators are the 1,4-benzodiazepines.
The method involves obtaining a multiple emulsion by injecting immiscible liquid phases under high turbulence. The device used for said purpose, which is called TROMS or 'Total Recirculation One-Machine System', comprises a pumping system (1) that is connected to a Rehodine  valve (2) from which two needles (3, 4) having different inner diameters stick out. The first needle is inserted into the first mixing vessel (5) and the other needle is inserted into the second mixing vessel (6). The organic phase is introduced into the system by means of a glass syringe with a Teflon plunger (7). The mixing vessels are connected to the pump by two valves (8 and 9). The method and device used are suitable for the production of homogenous microcapsule or heterogeneous microsphere type microparticles that are suitable for the encapsulation of water-soluble pharmaceuticals including plasmid DNA, RNA, genes, oligonucleotides, peptides, proteins and viral vectors used in genic therapy and defective recombinant adenovirus.
BACKGROUND: Corticosteroid injections (CSIs) are commonly used for the treatment of shoulder pain in patients with osteoarthritis and rotator cuff arthropathy. These injections may increase the risk of infection following eventual shoulder arthroplasty. The purpose of this study was to perform a systematic review and meta-analysis of existing data to explore the relationship between preoperative CSI's and postoperative periprosthetic joint infection (PJI) following shoulder arthroplasty.
METHODS: A literature search was performed on PubMed, Embase, and Web of Science databases through September 29, 2023. Of the 4221 retrieved, 7 studies including 136,233 patients were included for qualitative analysis. Studies describing patients receiving CSI prior to shoulder arthroplasty and the effect on postoperative infection risk were included in the systematic review and subsequent meta-analysis. Assessment of risk of bias was performed using the Methodological Index for Non-Randomized Studies (MINORS) criteria.
RESULTS: Receiving a CSI prior to shoulder arthroplasty was found to have a statistically significant association with increased risk for PJI (odds ratio [OR]: 1.13; 95% confidence interval [CI]: 1.06-1.19; P < .0001). The rate of PJI increased when injections were given closer to the time of surgery. Patients who received an injection at any time point before surgery had a 5.4% risk of PJI compared to 7.9% and 9.0% in patients receiving an injection within 3 months and 1 month of surgery, respectively. This time dependent association however did not reach statistical significance: 1 month OR 1.48; 95% Cl: 0.86-2.53; P = .16, 3 months OR 1.95; 95% Cl: 0.95-4.00; P = .07.
CONCLUSION: The results of this systematic review and meta-analysis demonstrate that patients receiving corticosteroid shoulder injections prior to shoulder arthroplasty may be at an increased risk for PJI postoperatively. While time dependent stratification did not reach statistical significance, our findings indicate a clear trend of increased risk for patients receiving injections closer to surgery.
Hydrocortisone hemisuccinate (Hydrocortisone Upjohn) was supplied as a powder in 100 mg vials to be reconstituted with 2 ml of sterile water diluent. The placebo was saline serum supplied as 10 ml ampoules. The study drugs were administered according to two protocols. In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days. In the two groups, hydrocortisone was stopped abruptly at the end of treatment. The investigators had the choice or resuming hydrocortisone at the end of the fifth day if deemed necessary.
The ketogenic diet (KD) is a form of therapy for seizures that involves a brief period of fasting followed by a very carefully controlled high fat-low protein and carbohydrate diet. Studies suggest it is useful in children whose seizures could not be controlled by any of the medicines available. This study is designed to test, in a carefully controlled fashion, how well the diet works in children with "drop" seizures. Children who experience 15 or more drop seizures each day, despite having used at least two medications, may be eligible to participate. This study requires children to undergo periods of fasting and to maintain a carefully controlled diet. Parents of participating children monitor their children's diets and keep daily meal and seizure diaries.
A method of producing mesenchymal stem cells from induced pluripotent stem cells in which induced pluripotent stem cells are cultured in the presence of a TGF-β inhibitor an in an atmosphere containing from about 7 vol. % to about 8 vol. % CO 2  for a period of time from about 20 day to about 35 days. The cells then are transferred to a culture dish having a hydrophilic surface, and the cells are cultured in a medium containing a TGF-β inhibitor for a period of time sufficient to produce mesenchymal stem cells. Such mesenchymal stem cells are more stable and less likely to form tumors, cancers, or teratomas. Also, the induced pluripotent stem cells may be genetically engineered with at least one polynucleotide encoding a therapeutic agent and then are cultured as hereinabove described to provide genetically engineered mesenchymal stem cells that express sustained amounts of a biologically active protein or polypeptide.
Pharmacologic approaches to increase levels or actions of the vasodilatory peptide Angiotensin (1-7) are currently in development for the treatment of hypertension based on findings from animal studies. There are limited and contradictory clinical studies, however, and it is unclear if this peptide even contributes to blood pressure regulation in humans. The purpose of this study is to learn more about the cardiovascular effects of Angiotensin (1-7) in essential hypertension, and to examine interactions of this peptide with the autonomic nervous system for blood pressure regulation. The investigators propose that the difficulties in showing Angiotensin (1-7) cardiovascular effects in previous clinical studies relates to the buffering capacity of the baroreceptor reflex to prevent changes in blood pressure. In this study, the investigators will test the hypothesis that Angiotensin (1-7) produces negligible effects with intact baroreceptors, and that the cardiovascular effects of this peptide are unmasked following elimination of baroreflex buffering. To test this hypothesis, the investigators will examine the effects of acute intravenous Angiotensin (1-7) infusion on blood pressure in subjects with essential hypertension under intact conditions and following acute autonomic withdrawal with the ganglionic blocker trimethaphan. The primary outcome will be the decrease in systolic blood pressure produced by Angiotensin (1-7) infusion, with comparisons made between intact and blocked study days. As a secondary objective, the investigators will examine for changes in systemic hemodynamics and circulating hormones in response to the Angiotensin (1-7) infusion, to determine potential mechanisms underlying any changes in blood pressure.
A method and a system for providing remote access to scanner utilization or diagnostic imaging reports generated by a computer system having access to a database of collected scanner operational data. Preferably, the reports are delivered over a wide-area network, e.g. the Internet, in response to requests for access from customers. In particular, the system includes a graphical user interface which allows the user to specify all of the report content parameters and display the report on a single screen. The report content parameters section of the screen allows the user to identify the facility, organization area (i.e., department), equipment, time dimension, time frame, metrics and data slices that the user wants included in the report. The report produced will contain the information currently in the database, which information is updated daily.
Patients undergo video-assisted thoracic surgery (VATS) lobectomy, which requires 3 small incisions on the side of the chest. The entire anatomic pulmonary lobe is removed, as well as all peribronchial lymph nodes and anterior hilar lymph nodes. If it is not possible to remove the lobe using the VATS approach, then 1 of the incisions is converted to a standard thoracotomy. Patients are followed every 4 months for the first 2 years, and then every 6 months for the next 3 years.
The experimental group will receive the intervention. First, the group will undergo a pre-intervention evaluation lasting 120 minutes. The intervention will consist of two synchronized virtual sessions of brief intervention with a cognitive-behavioral approach where various persuasive communication strategies will be implemented, definition of hazardous alcohol consumption, establishment of a consumption goal, social skills to deal with pressure to consume and plan of pleasant activities alternative to consumption, each session will last 120 minutes. Four weeks after the end of the intervention, the experimental group will carry out the post-intervention evaluation session in a virtual synchronized manner with a duration of 120 minutes.
A system for improving physical motor control of affected human extremities and related cognitive and nervous system processes improvement includes a computer device having a display device and an input device each disposed in communication with the computer device. The computer device is configured to display to a user at least one virtual body part that represents a corresponding body part portion of the user requiring improvement. The virtual body part(s) is shown in a first configuration on the display device. The computer device receives user input that causes the virtual body part(s) to move in a user-directed motion. The computer device displays the user-directed motion of the virtual body part to a second configuration based on the user input. The user repeats the user input to cause improvement of physical motor control of the corresponding body part of the user.
The invention discloses a pig lambda 3 interferon mutant and a preparation method and application thereof. The invention firstly discloses a pig lambda 3 interferon with an amino acid sequence shown as SEQ ID NO.1 and a coding gene thereof. The invention optimizes the codon of the pig lambda 3 interferon coding gene according to the codon preference of silkworm to obtain the optimized gene shown in SEQ ID NO.3 with improved antiviral activity. The invention further carries out amino acid single-site mutation, double-site mutation and multi-site mutation on the optimized gene shown in SEQ ID NO.3 respectively to obtain a plurality of porcine lambda 3 interferon mutants with remarkably improved antiviral activity. The invention uses the silkworm baculovirus expression system to express the pig lambda 3 interferon mutant in a silkworm bioreactor, and the antiviral activity of the expressed product is obviously improved. The porcine lambda 3 interferon mutant provided by the invention can be used for preparing a medicament or a reagent for preventing or treating porcine viral diseases.
PURPOSE: A composition containing extract of Chrysanthemum indicum Linne. and Rheum undulatum is provided to reduce cytokine secretion in atopic skin and to relieve atopic dermatitis symptom. CONSTITUTION: A pharmaceutical composition for preventing and treating atopic dermatitis contains mixture extract of Chrysanthemum indicum Linne. and Rheum undulatum as an active ingredient. A method for preparing Rheum undulatum comprises: a step of mixing Rhei Rhizoma pieces and Oryza sativa fruit wine; a step of steaming the mixture. The mixture extract is isolate using 1,3-butyelen glycol. A neutraceutical food for preventing and treating atopic dermatitis contains the mixture extract as an active ingredient. An external use skin formulation or cosmetic composition for preventing and treating atopic dermatitis contains the mixture extract as an active ingredient. The mixture extract is formed in a nanoliposome.
In one example, a method of transmitting biometric healthcare data is disclosed. A patient computing system is used to determine biometric healthcare data of a patient during a telemedicine video conference. The telemedicine video conference having a data stream to communicate telemedicine audio/visual data between the patient computing system and a remote healthcare provider computing system. A biometric healthcare video data stream containing the biometric healthcare data of the patient is generated. The biometric healthcare video data stream is composited with the data stream of the telemedicine video conference to create a composite data stream. The composite data stream is transmitted from the patient computing system to the remote healthcare provider computing system.
This arm will include the first 6 participants. In this group, a cut will be made near the eardrum and it will be lifted up so the surgeon can see the electrode as it goes into the cochlea.
ABSTRACT            Point mutations and/ or deletions in the human hypoxanthine-guanine phosphoribosyl transferase (HPRT) gene is believed to be the cause of Lesch-Nyhan syndrome  in humans;  however,  the disastrous neurological symptoms which are characteristic of this   disease   cannot   be   easily   explained   by   these mutations/deletions or even by the complete loss of the gene. There is no known cure for the disease. We reconstructed a cDNA (chprt) which is 100% homologous to a region of the antisense strand of hprt mRNA. The cDNA encodes a 30 amino acid protein (phrpt)  which appears  to be  an  intracellular  activator of proteins involved in human neurological diseases. Because of the antisense relation with hprt mRNA, phprt cannot be expressed in humans carrying a normal wild type hprt gene; however, mutations in critical  regions  of  the  hprt gene  can  stop  antisense repression and permit expression of phprt and the appearance of the pathophysiological symptoms of Lesch-Nyhan disease.  The antisense protein is a very good target for immunotherapeutic reagents to stop the devastating neurological processes caused in humans afflicted with Lesch-Nyhan.
Parents and teens randomly assigned to this arm of the trial will engage in a web-based training that provides parents with guidance on how to train their teen to identify potential hazards on the roadway. Parents are also given an opportunity to practice these new skills with teens when watching videos unfold together. The program will take 4 hours to complete and can be done over a two-week period at the parent's convenience.
Background: Enteral nutrition is the preferred method of artificial nutrition for critically ill patients. Early enteral nutrition within 24 to 48 hours after admission can maintain intestinal mucosal barrier function, increase local blood flow, reduce bacterial migration, and reduce the incidence of intestinal infections. Increased abdominal pressure is considered to be an independent risk factor for feeding intolerance in severe patients. Patients with abdominal pressure are prone to complications such as diarrhea, abdominal distension, vomiting, and even aspiration, which forces the suspension or suspension of enteral nutrition and leads to insufficient nutritional intake in patients. At present, there is evidence that regulating enteral nutrition through monitoring intra-abdominal pressure can effectively reduce the incidence of feeding intolerance in patients. Domestic and foreign scholars have formulated nutrition management programs for patients with intra-abdominal pressure from different aspects, such as monitoring and grading of intra-abdominal pressure, evaluation and management of tolerance, and prevention of complications. However, The standardized enteral nutrition feeding program oriented by the monitoring of intra-abdominal pressure has not yet formed a unified standard.

Objective: This study conducted a quality evaluation based on existing evidence, adopted evidence-based research methods to establish an enteral nutrition program for patients with abdominal hypertension oriented by abdominal pressure, and aimed to improve the feeding tolerance of patients with abdominal hypertension, improve the nutritional compliance rate and improve the prognosis of patients through the implementation of evidence-based practice programs.
The combined exercise session will be structured with 20 minutes of resistance exercise + 20 minutes of aerobic exercise, as already described, except that the resistance exercises will have 2 sets of each exercise. As with other sessions, blood pressure, heart rate and the Borg scale will be assessed at the beginning and end of the second series of resistance exercise, as well as at the beginning and every 5 minutes of aerobic exercise up to 15 minutes after end of exercises.
Herbal medicines, particularly traditional Chinese medicines (TCMs), are a rich source of natural products with significant therapeutic potential. However, understanding their mechanisms of action is challenging due to the complexity of their multi-ingredient compositions. We introduced Herb-CMap, a multimodal fusion framework leveraging protein-protein interactions and herb-perturbed gene expression signatures. Utilizing a network-based heat diffusion algorithm, Herb-CMap creates a connectivity map linking herb perturbations to their therapeutic targets, thereby facilitating the prioritization of active ingredients. As a case study, we applied Herb-CMap to Suhuang antitussive capsule (Suhuang), a TCM formula used for treating cough variant asthma (CVA). Using in vivo rat models, our analysis established the transcriptomic signatures of Suhuang and identified its key compounds, such as quercetin and luteolin, and their target genes, including IL17A, PIK3CB, PIK3CD, AKT1, and TNF. These drug-target interactions inhibit the IL-17 signaling pathway and deactivate PI3K, AKT, and NF-κB, effectively reducing lung inflammation and alleviating CVA. The study demonstrates the efficacy of Herb-CMap in elucidating the molecular mechanisms of herbal medicines, offering valuable insights for advancing drug discovery in TCM.
All patients operated on endocrine surgery in the three referral centers and responding to the inclusion criteria will be included after obtaining their writing consent. The gold standard NF will be performed between D1 and D15, as usually performed after these surgeries. TLU will be performed during the same time period by an investigator blind to the NF results. The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments.
Pediatric Patients

The efficacy of ABILIFY in the treatment of irritability associated with autistic disorder was established in two 8-week, placebo-controlled trials in pediatric patients (6 to 17 years of age) who met the DSM-IV criteria for autistic disorder and demonstrated behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. Over 75% of these patients were under 13 years of age.

Efficacy was evaluated using two assessment scales: The Aberrant Behavior Checklist (ABC) and the Clinical Global Impression-Improvement (CGI-I) scale. The primary outcome measure in both trials was the change from baseline to endpoint in the Irritability subscale of the ABC (ABC-I). The ABC-I subscale measured symptoms of irritability in autistic disorder.

The results of these trials are as follows:

In one of the 8-week, placebo-controlled trials, children and adolescents with autistic disorder (n=98), aged 6 to 17 years, received daily doses of placebo or ABILIFY 2 to 15 mg/day. ABILIFY, starting at 2 mg/day with increases allowed up to 15 mg/day based on clinical response, significantly improved scores on the ABC-I subscale and on the CGI-I scale compared with placebo. The mean daily dose of ABILIFY at the end of 8-week treatment was 8.6 mg/day (Study 1 in Table 26).

In the other 8-week, placebo-controlled trial in children and adolescents with autistic disorder (n=218), aged 6 to 17 years, three fixed doses of ABILIFY (5 mg/day, 10 mg/day, or 15 mg/day) were compared to placebo. ABILIFY dosing started at 2 mg/day and was increased to 5 mg/day after one week. After a second week, it was increased to 10 mg/day for patients in the 10 and 15 mg dose arms, and after a third week, it was increased to 15 mg/day in the 15 mg/day treatment arm (Study 2 in Table 26). All three doses of ABILIFY significantly improved scores on the ABC-I subscale compared with placebo.
Dose Escalation Group plus additional 36 participants for Azacitidine 75 mg/m2 (or Phase I MTD) either subcutaneous or intravenous every day for 3 days of 28 day cycle. TKI at dose received during last 6 months.